Shield Therapeutics Plc
Total Valuation
USDAs of June 30, 2026, Shield Therapeutics PLC carries a market capitalization of 85.59M, placing it among publicly traded companies globally. Its enterprise value stands at 105.25M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 85.59M |
| Enterprise Value | 105.25M |
Important Dates
Shield Therapeutics PLC's next confirmed earnings release is scheduled for April 29, 2027.
| Earnings Date | 4/29/2027 |
Share Statistics
As of June 30, 2026, Shield Therapeutics PLC has 1.07B shares outstanding.
| Shares Outstanding | 1.07B |
Valuation Ratios
These figures are as of June 30, 2026.
| PB Ratio | -5.03 |
| P/TBV Ratio | -2.43 |
Financial Position
As of June 30, 2026, Shield Therapeutics PLC maintains a current ratio of 0.75, meaning it holds 0.8x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 0.75 |
| Quick Ratio | 0.18 |
| Debt / Equity | -164.50 |
Financial Efficiency
These figures cover the twelve months ended June 30, 2026.
| Employee Count | 61.00 |
Stock Price Statistics
USDAs of the close on October 13, 2026, Shield Therapeutics PLC's stock has declined approximately 24.52% over the past 52 weeks.
| 52-Week Price Change | -24.52% |
| 50-Day Moving Average | 0.09 |
Balance Sheet
USDAs of June 30, 2026, Shield Therapeutics PLC holds 8.35M in cash and equivalents against 28.01M in total debt, resulting in a net debt position of 19.66M. Total book value stands at -17.02M, with working capital of -11.40M providing operational flexibility.
| Cash & Cash Equivalents | 8.35M |
| Total Debt | 28.01M |
| Net Debt | 19.66M |
| Equity (Book Value) | -17.02M |
| Book Value Per Share | -0.02 |
| Working Capital | -11.40M |
Stock Splits
Shield Therapeutics PLC's most recent stock split took place on December 16, 2022 with a 34:35 split ratio.
| Last Split Date | 12/16/2022 |
| Split Ratio | 34:35 |